Atibuclimab  (Synonyms: 阿替布利单抗; IC14)

Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury^[1][2].

CD14

Atibuclimab (IC14) 可识别膜结合型 CD14 (mCD14) 和可溶性 CD14 (sCD14)^[1]。
分化簇 14 (CD14) 是一种存在于髓系细胞表面的糖蛋白。CD14 是几种 Toll 样受体 (TLR) 的辅助分子，TLR 是一个模式识别受体家族，可对与炎症和组织损伤相关的病原体和人类分子中的保守模式作出反应。 CD14 是革兰氏阴性菌和革兰氏阳性菌细胞壁成分的受体，参与脓毒症炎症反应的启动^[1][2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

929  [NCBI]

P08571

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.5 kDa

2417175-94-9

液体

Colorless to light yellow

阿替布利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized CD14 Protein, Human (HEK293, His, HY-P7786) can bind Atibuclimab. The EC₅₀ for this effect is 22.13 ng/mL.

• [1]. Henderson RD, Agosti JM, McCombe PA, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore). 2021;100(42):e27421.  [Content Brief]

  [2]. Verbon A, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol. 2001;166(5):3599-3605.  [Content Brief]